DR REDDY'S Q2 : CONS NET PROFIT DOWN 36% AT 925 CR (YOY), UP 109% (QOQ). MIX (ON 1ST LOOK)

Revenue down 1.5% at ₹8,670.8 Cr (YOY), up 7.4% (QOQ). Ebitda down 24% at ₹1,782.8 Cr (YOY); margins 20.6% v 26.7% (YOY), 12.5% (QOQ). Gross margin 52.1% v 54.7% (YOY), 46.5% (QOQ). PAT margin 10.7% v 16.3% (YOY); PBT at ₹1,227.7 Cr. Caution: Q1FY27 was hit by a ₹239.7 Cr provision on semaglutide API inventory and associated costs, which flatters the QoQ jump.

Dr Reddys Laboratories Ltd

Open attachment

← Back to feed